CompletedNCT00048360
Extended-release bupropion for adults with ADHD
About this title
Read the official source — NCT00048360Medication studyAges 18–60United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- Phoenix and 20 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2002
- Recruitment status
- Completed
- Enrollment listed in the registry
- 162
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00048360
- Official title
Show the full official title
An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/Day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix · Chula Vista · Lafayette
18 more locations
- Northridge
- Spring Valley
- West Palm Beach
- Paducah
- Rockville
- Cambridge
- Worcester
- Omaha
- Chapel Hill
- Beachwood
- Cincinnati
- Portland
- Bellaire
- Houston
- Salt Lake City
- Burlington
- Woodstock
- Seattle
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including Extended-release bupropion hydrochloride.
Who was this study for?
Listed age limits: 18 years to 60 years.
